<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4951">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04407000</url>
  </required_header>
  <id_info>
    <org_study_id>NOV2020/01925</org_study_id>
    <nct_id>NCT04407000</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Favipiravir 200 mg Film Tablet (World Medicine, Turkey) Under Fasting Conditions</brief_title>
  <acronym>Favipiravir</acronym>
  <official_title>Open-label,Randomised,Single Oral Dose,Two-period,Cross-over Trial to Assess to Bioequivalence of Loqular 200 mg FT in Comparison With Avigan 200 mg FT in Healthy Male Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>World Medicine ILAC SAN. ve TIC. A.S.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novagenix Bioanalytical Drug R&amp;D Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Farmagen Ar-Ge Biyot. Ltd. Sti</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>World Medicine ILAC SAN. ve TIC. A.S.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single dose of Reference product containing 200 mg favipiravir and a single dose of Test&#xD;
      product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at&#xD;
      room temperature, in each period under fasting conditions with current pandemic precautions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Favipiravir is a drug with a mechanism of action different from that of the existing&#xD;
      influenza antiviral drugs and effective against all types and sub-types of human influenza A,&#xD;
      B and C viruses in vitro, showing anti-viral activity against various influenza virus strains&#xD;
      including avian and swine viruses. Favipiravir also has shown anti-viral activity even&#xD;
      against amantadine, oseltamivir and zanamivir-resistant influenza viruses in vitro. The&#xD;
      mechanism of action of favipiravir is the selective inhibition of RNA polymerase by&#xD;
      favipiravir ribosyl triphosphate formed by cellular enzymes in the influenza virus leading to&#xD;
      antiviral activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2020</start_date>
  <completion_date type="Actual">August 8, 2020</completion_date>
  <primary_completion_date type="Actual">July 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary PK End Points AUC0-tlast</measure>
    <time_frame>12 weeks</time_frame>
    <description>AUC0-tlast of favipiravir</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary PK End Points Cmax</measure>
    <time_frame>13 weeks</time_frame>
    <description>Cmax of favipiravir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary PK End Points AUC0-inf</measure>
    <time_frame>14 weeks</time_frame>
    <description>AUC0-inf of favipiravir</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary PK End Points tmax</measure>
    <time_frame>15 weeks</time_frame>
    <description>tmax of favipiravir</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Test Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loqular 200 mg Film Tablet containing 200 mg favipiravir (World Medicine İlaç-Turkey)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Avigan 200 mg Film Tablet containing 200 mg favipiravir (Toyama Chemical Industry Co.Ltd./Japan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test: Favipiravir 200 mg (LOQULAR)</intervention_name>
    <description>Test Drug</description>
    <arm_group_label>Test Drug</arm_group_label>
    <other_name>LOQULAR 200 MG FT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference: Favipiravir 200 mg (Avigan)</intervention_name>
    <description>Reference Drug</description>
    <arm_group_label>Reference drug</arm_group_label>
    <other_name>Avigan 200 mg Film Tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy Caucasian male subjects aged between 20 and 40 years,&#xD;
&#xD;
          2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink&#xD;
             coffee during the study period,&#xD;
&#xD;
          3. Two Negative Covid-19 PCR test results.&#xD;
&#xD;
          4. Negative alcohol breath test results,&#xD;
&#xD;
          5. Normal physical examination at screening visit,&#xD;
&#xD;
          6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in&#xD;
             the desirable range according to the age,&#xD;
&#xD;
          7. Ability to communicate adequately with the investigator himself or his&#xD;
             representatives,&#xD;
&#xD;
          8. Ability and agreement to comply with the study requirements,&#xD;
&#xD;
          9. Normal blood pressure and heart rate measured under stabilised conditions at the&#xD;
             screening visit after at least 5 minutes of rest under supine position: SBP within 100&#xD;
             to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,&#xD;
&#xD;
         10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of&#xD;
             rest,&#xD;
&#xD;
         11. Laboratory results within normal range or clinically non-significant (CBC, glucose,&#xD;
             urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium,&#xD;
             calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein&#xD;
             and urinalysis), drug addiction scanning in urine results in negative (amphetamine,&#xD;
             barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),&#xD;
&#xD;
         12. Understanding of the study and agreement to give a written informed consent according&#xD;
             to section 20.3.&#xD;
&#xD;
         13. Understanding of that he and his partner will use a practice adequate contraception&#xD;
             during the study and at least 7 days after the study.&#xD;
&#xD;
         14. Volunteer's compliance with isolation rules defined at study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Who have atopic constitution or asthma or known allergy for favipiravir and/or any&#xD;
             other ingredients of the products.&#xD;
&#xD;
          2. Who have positive Covid-19 PCR test result.&#xD;
&#xD;
          3. Any history or presence of clinical relevance of cardiovascular, neurological,&#xD;
             musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary,&#xD;
             endocrinological, metabolism or psychiatric disease, any type of porphyria.&#xD;
&#xD;
          4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first&#xD;
             drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10&#xD;
             mmHg occurs between sitting/supine to standing position subject will be excluded (if&#xD;
             it deemed necessary by the investigator),&#xD;
&#xD;
          5. Presence or history of malabsorption or any gastrointestinal surgery except&#xD;
             appendectomy or except herniotomy.&#xD;
&#xD;
          6. Subjects who have given more than 400 mL blood within the last two months before the&#xD;
             first drug administration and subjects who have participated to any drug research&#xD;
             within the last two months before the first drug administration.&#xD;
&#xD;
          7. Subjects suspected to have a high probability of non-compliance to the study procedure&#xD;
             and/or completion of the study according to the investigator's judgement.&#xD;
&#xD;
          8. Subjects who used any of prescribed systemic or topical medication (including OTC&#xD;
             medication) within 2 weeks (or six elimination half lives of this medication,&#xD;
             whichever is longer) before the initiation of the study (except single doses of&#xD;
             analgesics which have no drug interaction with study product).&#xD;
&#xD;
          9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the&#xD;
             study medication.&#xD;
&#xD;
         10. History of allergic response to heparin.&#xD;
&#xD;
         11. Subjects who have any chronic disease which might interfere with absorption,&#xD;
             distribution, metabolism or excretion of the drug.&#xD;
&#xD;
         12. Subjects who regular consumed of beverages or food containing methylxanthines (e.g.&#xD;
             coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg&#xD;
             methylxanthines per day.&#xD;
&#xD;
         13. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug&#xD;
             administration, during the study.&#xD;
&#xD;
         14. History of drug abuse.&#xD;
&#xD;
         15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or&#xD;
             10 units per week and/or positive alcohol breath test results (Note: one unit of&#xD;
             alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).&#xD;
&#xD;
         16. Positive blood test for HBV, HCV and HIV.&#xD;
&#xD;
         17. Who have relationship to the investigator.&#xD;
&#xD;
         18. Who are not suitable to any of inclusion criteria.&#xD;
&#xD;
         19. History of difficulty of swallowing.&#xD;
&#xD;
         20. Intake of depot injectable solutions (including study medications) within 6 months&#xD;
             before start of the study.&#xD;
&#xD;
         21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before&#xD;
             start of the study.&#xD;
&#xD;
         22. Special diet due to any reason, e.g. vegetarian.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Muradiye Nacak, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Farmagen Ar-Ge Biyot. Ltd. Sti</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novagenix Drug R&amp;D Center</name>
      <address>
        <city>Akyurt</city>
        <state>Ankara</state>
        <zip>06970</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Farmagen Ar-Ge Biyot. Ltd. Sti.</name>
      <address>
        <city>Sahinbey</city>
        <state>Gaziantep</state>
        <zip>27000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 24, 2020</study_first_submitted>
  <study_first_submitted_qc>May 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>August 8, 2020</last_update_submitted>
  <last_update_submitted_qc>August 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19 drug treatment</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Favipiravir</keyword>
  <keyword>Novagenix</keyword>
  <keyword>Farmagen</keyword>
  <keyword>World Medicine</keyword>
  <pending_results>
    <submitted>December 13, 2020</submitted>
    <returned>December 18, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

